Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep376 | Clinical case reports - Thyroid/Others | ECE2016

To be or not to be … male

Capraro Joel , Schutz Philipp

Introduction: Pats with Klinefelter Syndrome (KS) have elevated morbidity and mortality due to several reasons. Yet, there is no connection between KS and male-to-female sex change.Case: A 74-year-old man was sent for endocrine work-up prior to surgery due to gynecomastia. The patient had lived as a man-to-woman transgender for many years. He was told not to qualify for a transgender surgical approach when he was 55 years old. He took estradiol substitut...

ea0049oc11.3 | Obesity | ECE2017

Interleukin-1 antagonism decreases cortisol levels in obese individuals

Urwyler Sandrine , Schutz Philipp , Ebrahimi Fahim , Donath Marc Y. , Christ-Crain Mirjam

Background: Increased cortisol levels in obesity may contribute to the associated metabolic syndrome. In obesity, the activated innate immune system leads to increased interleukin (IL)-1β, which is known to stimulate the release of adrenocorticotropin hormone (ACTH). We therefore hypothesised that in obesity IL-1 antagonism would result in downregulation of the hypothalamo-pituitary-adrenal (HPA) axis, leading to decreased cortisol levels.Methods: I...

ea0041oc4.5 | Thyroid - Clinical | ECE2016

Risk factors of relapse in Graves’ disease? Results from a systematic review and meta-analysis

Struja Tristan , Fehlberg Hannah , Kutz Alexander , Gubelin Larissa , Degen Christian , Muller Beat , Schutz Philipp

Context: Identification of risk factors predicting relapse in patients with hyperthyroidism of Graves’ disease after the first cycle with standard thyreostatic therapy [ATD] is important to guide therapeutic options.Objective: We performed a systematic review and meta-analysis to study predictors for risk of relapse after the first treatment episode with ATD in patients with Graves’ disease induced hyperthyroidism.Data so...

ea0041ep1003 | Thyroid (non-cancer) | ECE2016

Does Immunosuppressive Therapy improve outcomes in Graves’ disease: Results from a Systematic Review and Meta-analysis

Struja Tristan , Gubelin Larissa , Kutz Alexander , Fehlberg Hannah , Muller Beat , Schutz Philipp

Objective: Whether additional immunosuppressive drugs to standard treatment with thyreostatic drugs reduce the risk for relapse in Graves’ disease is not well understood. We performed a systematic review and meta-analysis to study the effects of immunosuppressive drugs on relapse rate and treatment effect of patients with hyperthyroidism due to Graves’ disease.Methods: We searched PubMed, EMBASE and Cochrane in July 2015 for randomized-controll...

ea0037gp.17.06 | Pituitary–Neuroendocrinology and central salt regulation | ECE2015

Predictors of response to fluid restriction in hyponatremic patients due to the syndrome of inappropriate antidiuresis

Lengsfeld Sophia , Winzeler Bettina , Nigro Nicole , Suter-Widmer Isabelle , Schutz Philipp , Arici Birsen , Bally Martina , Blum Claudine , Bock Andreas , Huber Andreas , Muller Beat , Christ-Crain Mirjam

Introduction: Fluid restriction (FR) is often the recommended first-line treatment for hyponatremia due to the syndrome of inappropriate antidiuresis (SIAD). However, FR not always leads to successful correction of hyponatremia, making predictive markers of treatment response desirable. The aim of this study was to evaluate routinely measured laboratory parameters, copeptin and pro-atrial natriuretic peptide (pro-ANP) as possible predictors of treatment success to FR.<p cl...

ea0041gp154 | Pituitary - Clinical | ECE2016

Outcome predictors in profound hyponatremia – a prospective 12-month-follow-up study

Frech Nica , Winzeler Bettina , Nigro Nicole , Suter-Widmer Isabelle , Schutz Philipp , Arici Birsen , Bally Martina , Blum Claudine , Nickel Christian , Bingisser Roland , Bock Andreas , Huber Andreas , Muller Beat , Christ-Crain Mirjam

Introduction: Hyponatremia is the most common electrolyte abnormality in clinical practice and given its impact on mortality and morbidity a relevant medical condition. Nevertheless little is known about factors influencing long-term outcome.Methods: This is a prospective observational 12 months follow-up study of patients with profound hyponatremia (≤125 mmol/l) admitted to the medical emergency department of two tertiary care centers in Switzerla...

ea0029n3 | (1) | ICEECE2012

Interdisciplinary risk assessment and patient discharge management: combining biomarker & clinical scores, medical & nursing aspects

Conca Antoinette , Schild Ursula , Regez Katharina , Bossart Rita , Tobias Petra , Wallimann Gabriela , Schweingruber Ruth , Reutlinger Barbara , Albrich Werner , Ruegger Kristina , Dusemund Frank , Schutz Philipp , Huber Andreas , Burgi Ulrich , Muller Beat

Introduction: Current medical and nursing scores have limited efficiency and safety profiles to assign the most appropriate treatment site to patients with lower respiratory tract infections (LRTIs). We assessed the potential of a combined score of CURB65 with proadrenomedullin (ProADM) levels and the adapted post-acute discharge score (PACD) for triage and discharge management decisions. We aimed to identify the proportions of patients who would be best cared for at different...

ea0081oc1.3 | Oral Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Canakinumabin patients with COVID-19 and type 2 diabetes (CanCovDia) – a multicentric, randomised, double-blind, placebo-controlled phase 3 trial

Hepprich Matthias , Mudry Jonathan , Gregoriano Claudia , Jornayvaz Francois R , Carballo Sebastian , Wojtusciszyn Anne , Bart Pierre-Alexandre , Chiche Jean-Daniel , Fischli Stefan , Baumgartner Thomas , Cavelti-Weder Claudia , Beuschlein Felix , Braun Dominque L , Gunthard Huldrych F , West Emily , Conen Anna , Isenring Egon , Bucklar Gabriela , Aubry Yoann , Dey Ludovic , Muller Beat , Schutz Philipp , Cattaneo Marco , Hunziker Patrick , Donath Marc Y

Background: Patients with type 2 diabetes and overweight have a chronic activation of the innate immune system possibly explaining the increased risk of a hyperinflammatory response and severe COVID-19. We aimed to test whether blockade of interleukin-1β(IL-1β) using canakinumab improves clinical outcome.Methods: CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-o...